Medical Aid in Dying: Choosing a Compounded Protocol After Secobarbital
A patient approved for medical aid in dying has to choose among compounded multi-drug regimens built to replace a barbiturate that no longer exists on the market — and the choice trades a slower, more familiar drug combination against a faster one with a thinner safety record.
Renata O. spent forty years throwing pottery in a converted garage studio, and the last piece she finished — a wide, unglazed bowl she calls unfinished on purpose — sits on the table between her and the two clinicians going through her aid-in-dying paperwork one final time. Her metastatic pancreatic cancer was diagnosed eight months ago, already unresectable; two prognosis-confirming visits are done, the fifteen-day waiting period has passed, and what remains is the actual pharmacology of the day itself, which nobody explained to her in detail until now.
Secobarbital, the drug her state's law was written around, has not been commercially available since 2019, and every patient exercising this option since has been routed to compounded multi-drug regimens instead. DDMP2 — digoxin, diazepam, morphine, and propranolol, mixed to a bitter oral suspension — was the first widely adopted replacement, and Oregon's own reporting shows why it is no longer the default: a median time to death of 85 minutes in 2020 against 25 minutes for secobarbital, with the Academy's own registry putting more than a third of DDMP2 cases past the two-hour mark and documented outliers running past a full day. DDMAPh, which swaps propranolol for amitriptyline and adds phenobarbital, cut the maximum recorded time to death from 12.4 hours to 5.1 hours in the largest case series published on the substitution. The remaining open question, and the one actually dividing the two clinicians at her table, is not which four-drug base to use — that much is settled — but whether the digoxin should go in mixed with everything else or be given alone thirty minutes ahead of it, a sequencing choice one advocacy registry credits with a one-third reduction in mean time to death — measured, though, in the propranolol-based DDMP2 protocol nobody at this table is proposing, never inside a phenobarbital regimen, and reasoned from absorption kinetics rather than a randomized comparison.
Renata has read the same registry data her clinicians have — she asked for it herself two visits ago — and her own stated priority isn't the fastest possible protocol but the most predictable one, given that her son is flying in from out of state specifically to be present and has a return flight booked forty-eight hours later. A regimen with a documented outlier tail stretching past a day is, to her, a worse outcome than a slower but tighter distribution, which is part of why the conversation has moved past DDMP2 entirely and settled on the phenobarbital-containing base; what remains genuinely open is only the sequencing question, and how much weight a mechanistic argument without a randomized comparison behind it should carry against a well-documented, if slower, standard.
At the kitchen table, three days before the scheduled date
I want to use the standard merged DDMAPh suspension — digoxin folded in with everything else, one ingestion, done. It's the best-documented phenobarbital protocol we have; the case series that dropped the maximum time to death from 12.4 to 5.1 hours used this exact merged formulation. And the one-third figure comes from D-DMP2 measured against DDMP2 — a propranolol regimen none of us is proposing. It has never been measured inside a phenobarbital protocol at all. I don't want to layer a timing refinement borrowed from a different formulation onto a decision this final without a stronger evidence base behind it.
The case series you're citing is real, but it wasn't testing merged versus separated digoxin against each other — it was testing phenobarbital-containing regimens against the older non-phenobarbital ones. The pre-digitalis question is a separate, later finding, and the mechanism behind it isn't speculative: digoxin is a hundred milligrams inside a suspension carrying twenty-nine grams of other active drug. And borrowing across formulations cuts the other way here — Shavelson's original pre-digitalis argument was made against DDMP2's eighteen grams. The phenobarbital base you want is heavier, not lighter, so if crowding explains the absorption failure, it explains more of it in your protocol than in the one the number came from. Absorption of a hundred milligrams against that much co-administered mass is a real pharmacokinetic problem, not a theoretical one.
There's a legitimate safety worry raised about early digitalis — that a conscious patient could, in principle, experience early digoxin toxicity before the sedatives take effect. I take that seriously as a hypothesis. But it hasn't shown up as a real event across the registry cases using this sequence, and I'd rather give the digoxin the chance to actually absorb than protect against a complication that so far exists only on paper.
You're both arguing pharmacology, and you're both right on the mechanism. But this whole plan lives or dies on whether Renata can manage a second, separately timed ingestion herself thirty minutes after the first, unassisted, in a state law that requires self-administration throughout. I spent forty minutes with her yesterday. Her hands shake by early afternoon and she tires audibly after any sustained task — that's not a reason to abandon the option, but it is a reason to ask her directly rather than assume either protocol on her behalf.
Agreed after Renata was asked directly, in front of both clinicians: she said plainly that she'd rather take the extra step if it meant a shorter, more predictable process, and that her daughter would hand her the second cup. Pre-dosed digoxin thirty minutes ahead of the DDMAPh suspension, ondansetron an hour before that, family and hospice nurse present throughout, nurse not administering.
Not agreed: the Hospice Medical Director's underlying discomfort with recommending a sequencing refinement that no randomized trial has tested wasn't resolved by Renata's answer — he still believes the merged protocol should stay the default recommendation for the next patient who doesn't ask, and said so. The Clinical Pharmacologist's mechanistic case was accepted as sound for this patient specifically, not adopted as a new standing house protocol.